Study the Lipoxygenase Enzyme Activity on Patients With  Thalassemia in Kirkuk Governorate

Wisam Sbhan Khalf Mohamed Aljumaily; Khalaf Naeef Mohamed

doi:10.61132/obat.v3i1.968

Authors

Wisam Sbhan Khalf Mohamed Aljumaily Kirkuk University
Khalaf Naeef Mohamed Ministry of Education

DOI:

https://doi.org/10.61132/obat.v3i1.968

Keywords:

Lipoxygenase, Thalassemia, Kirkuk

Abstract

This study was conducted at the Thalassemia Center of Azadi Educational Hospital, Kirkuk Health Directorate, Iraq, from June 1, 2024, to October 1, 2024. The study sample included 75 individuals, both males and females, aged between 4 and 67 years, divided into two groups: the first group comprised 50 thalassemia patients, while the control group included 25 healthy individuals. The results indicated a significant effect of thalassemia on the studied variables, as the disease led to increased levels of white blood cells, erythrocyte sedimentation rate, total iron-binding capacity, malondialdehyde, iron concentration, and lipoxygenase enzyme, recording values of 10.9 × 10³ cells/mL, 25.36%, 321.84 µg/dL, 721.12 mmol/L, 2788.9 ng/dL, and 226.2 IU/L, respectively. In contrast, thalassemia reduced hemoglobin levels to 8.57 g/L. The gender category significantly affected both malondialdehyde and iron concentrations, while the age category significantly impacted white blood cell levels, total iron-binding capacity, serum iron, and lipoxygenase enzyme. Among the interactions, the most influential factor was found in the group of female patients over 30 years old, who recorded the highest significant concentrations of white blood cells and malondialdehyde, reaching 12.26 × 10³ cells/mL and 1090 mmol/L. Conversely, female patients under 15 years showed the highest significant averages for the percentage of erythrocyte sedimentation rate and iron concentration, at 28% and 3270 ng/dL, respectively. Meanwhile, female patients aged 15-30 years exhibited the highest significant concentrations for total iron-binding capacity and lipoxygenase enzyme, at 361.8 µg/dL and 234 IU/L, respectively. Male patients aged 15-30 years recorded the lowest significant hemoglobin concentration, which was 7.33 g/L.

Downloads

Download data is not yet available.

References

Ali, S., Mumtaz, S., Shakir, H. A., Khan, M., Tahir, H. M., Mumtaz, S., et al. (2021). Current status of beta-thalassemia and its treatment strategies. Molecular Genetics and Genomic Medicine, 9(11), e1788. https://doi.org/10.1002/mgg3.1788

Al-Zubaidi, K. M. D., & Al-Jubouri, K. K. A. (2022). Biostatistics. Al-Hawija Agricultural College, University of Kirkuk, First Edition, 471 pages.

Azeez, F. S., Kamel, N. K., & Mahdi, N. B. (2016). Growth hormone and some other parameters estimation in thalassemia major patients. Kirkuk University Journal of Scientific Studies, 11(1), 64-74.

Che Yaacob, N. S., Islam, M. A., Alsaleh, H., Ibrahim, I. K., & Hassan, R. (2020). Alpha-hemoglobin stabilizing protein (AHSP): A modulatory factor in β-thalassemia. International Journal of Hematology, 111, 352.

Fibach, E., & Dana, M. (2019). Oxidative stress in β-thalassemia. Molecular Diagnosis & Therapy, 23, 245–261. https://doi.org/10.1007/s40291-018-0373-5

Gattermann, N., et al. (2021). The evaluation of iron deficiency and iron overload. Deutsches Ärzteblatt International, 118(49), 847.

Hennesy, D. J., Gary, R., Smith, F. E., & Thompson, S. L. (1984). Ferene: A new spectrophotometric reagent for iron. Canadian Journal of Chemistry, 62, 721-724.

Kattamis, A., Forni, G. L., Aydinok, Y., & Viprakasit, V. (2020). Changing patterns in the epidemiology of β-thalassemia. European Journal of Haematology, 105, 692–703. https://doi.org/10.1111/ejh.13498

Koonyosying, P., Fucharoen, S., & Srichairatanakool, S. (2020). Nutraceutical benefits of green tea in beta-thalassemia with iron overload. In Beta Thalassemia (pp. 119-129). IntechOpen.

Kuhn, M. J., Mavangira, V., & Sordillo, L. M. (2021). Cytochrome P450 enzyme involvement in health and inflammatory-based diseases of dairy cattle: An invited review. Journal of Dairy Science, 104(2), 1276-1290.

Li, J., Cao, F., Yin, H.-L., Huang, Z.-J., Lin, Z.-T., Mao, N., et al. (2020). Ferroptosis: Past, present and future. Cell Death & Disease, 11, 88. https://doi.org/10.1038/s41419-020-2298-2

Manda, G., Rojo, A. I., Martínez-Klimova, E., Pedraza-Chaverri, J., & Cuadrado, A. (2020). Nordihydroguaiaretic acid: From herbal medicine to clinical development for cancer and chronic diseases. Frontiers in Pharmacology, 11, 151. https://doi.org/10.3389/fphar.2020.00151

Marengo-Rowe, A. J. (2007). The thalassemias and related disorders. Baylor University Medical Center Proceedings, 20, 27–31. https://doi.org/10.1080/08998280.2007.11928085

Mulish, R. K., Al-Nimer, M. S., & Al-Zamely, O. M. Y. (2002). The level of malondialdehyde after activation with (H2O and CuSO4) and inhibition by desferrioxamine and molsidomine in the serum of patients with acute myocardial infarction. Natural Journal of Chemistry, 5, 139-148.

Powers, L. W. (1989). Diagnostic hematology: Clinical and technical principles. C.V. Mosby Company.

Shahid, W., Ejaz, S. A., Al-Rashida, M., Saleem, M., Ahmed, M., Rahman, J., ... & Ashraf, M. (2021). Identification of NSAIDs as lipoxygenase inhibitors through highly sensitive chemiluminescence method, expression analysis in mononuclear cells and computational studies. Bioorganic Chemistry, 110, 104818. https://doi.org/10.1016/j.bioorg.2020.104818

Shastry, B. S., & Rao, M. A. R. (1975). Studies on lipoxygenase from rice bran. Cereal Chemistry, 52(5), 597-603.

Shukla, U., Ujjaliya, N., Gupta, P., Khare, V., Yadav, B., Rai, A. K., ... & Dhiman, K. S. (2020). Efficacy and safety of Guduchighana Vati in asymptomatic and mild-to-moderate cases of coronavirus disease-19: A randomized controlled pilot study. AYU, 41(3), 188-196.

Sousa, L., et al. (2020). Iron overload: Effects on cellular biochemistry. Clinical Chimica Acta, 504, 180-189.

Stockwell, B. R. (2022). Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications. Cell, 185, 2401–2421. https://doi.org/10.1016/j.cell.2022.06.003

Taher, A. T., Weatherall, D. J., & Cappellini, M. D. (2018). Thalassaemia. The Lancet, 391, 155–167. https://doi.org/10.1016/S0140-6736(17)31822-6

Talaro, K. P. (2005). Immunization and immune assays. In Foundations in Microbiology (5th ed., pp. 490-491). McGraw Hill.

Tawfeeq, A. A. (2017). A prospective study for the outcomes of thalassemia in Kirkuk 2016. Kirkuk University Journal of Scientific Studies, 12, 140-156.

Tietz, N. W. (1999). Textbook of clinical chemistry (3rd ed.). C.A. Burtis, E.R. Ashwood, W.B. Saunders.

Turgeon, M. L. (1990). Clinical hematology: Theory and practice. Little Brown.

Vaezi, M. F., Fass, R., Boeckxstaens, G. E., El-Serag, H., Rosen, R., & Sifrim, D. (2021). Gastro-oesophageal reflux disease. Nature Reviews Disease Primers, 7(1), 55. https://doi.org/10.1038/s41572-021-00304-7

Wang, B., Wu, L., Chen, J., Dong, L., Chen, C., Wen, Z., et al. (2021). Metabolism pathways of arachidonic acids: Mechanisms and potential therapeutic targets. Signal Transduction and Targeted Therapy, 6, 94. https://doi.org/10.1038/s41392-020-00443-w

Weatherall, D. J. (2018). The evolving spectrum of the epidemiology of thalassemia. Hematology/Oncology Clinics of North America, 32, 165–175. https://doi.org/10.1016/j.hoc.2017.11.003

Wood, I., Trostchansky, A., & Rubbo, H. (2020). Structural considerations on lipoxygenase function, inhibition and crosstalk with nitric oxide pathways. Biochimie, 178, 170-180. https://doi.org/10.1016/j.biochi.2020.06.003